Moderna 's ( MRNA -2.63%) stock fell by 13% on Sept. 12 upon the announcement of extensive cost cuts that would affect a ...

Moderna is deprioritizing certain parts of its pipeline, which involves pausing work on some products and scrapping others.

With the stock now more than cut in half from its 52-week high, the company recently laid out a plan for its business at its ...

Moderna stock tumbled again Friday on a series of downgrades and price-target cuts following a "tough update" at its R&D Day.

Now, let's get back to our question. Is the stock a buy or a sell? This depends a lot on your own particular investment ...

Moderna’s cost-reduction plans, pipeline cuts and reined-in financial guidance, unveiled Thursday, triggered a wave of ...

NACI added that anyone above 6 months of age who isn't considered high risk "may receive the most recently updated vaccine in ...

Moderna shares are down for the second day in a row after the company said it would slash its research and development costs.

In terms of liquidity and interest, the mean open interest for Moderna options trades today is 1286.5 with a total volume of ...

Moderna pushed back its break-even goal by two years on Thursday as it delayed the timeline for developing several key ...

Shares of Moderna tumbled early Thursday after the vaccine developer said it was cutting research and development spending ...

The therapeutic vaccine, codenamed mRNA-4359, is intended to boost people's immunity to a variety of advanced solid tumor ...